

Polypharmazie in der Behandlung der Schizophrenie

Thomas Messer, Pfaffenhofen, und Max Schmauss, Augsburg

Literatur

- Addington D, Addington J, Patten S, et al. Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia. *J Clin Psychopharmacol* 2002;22:20–5.
- Afshar H, Roohafza H, Mousavi G, et al. Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. *J Psychopharmacol* 2009;23:157–62.
- Agelink MW, Kavuk I, Ak I. Clozapine with amisulpride for refractory schizophrenia. *Am J Psychiatry* 2004;161:924–5.
- Allen SA. Effect of chlorpromazine and clozapine on plasma concentrations of haloperidol in a patient with schizophrenia. *J Clin Pharmacol* 2000;40:1296–7.
- Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. *J Clin Psychiatry* 2005;66:63–72.
- Arango C, Kirkpatrick B, Buchanan RW. Fluoxetine as an adjunct to conventional antipsychotic treatment of schizophrenia patients with residual symptoms. *J Nerv Ment Dis* 2000;188:50–3.
- Assion HJ, Reinbold H, Lemanski S, et al. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. *Pharmacopsychiatry* 2008;41:24–8.
- Atre-Vaidya N, Taylor MA. Effectiveness of lithium in schizophrenia: do we really have an answer? *J Clin Psychiatry* 1989;50:170–3.
- Baandrup L, Gasse C, Jensen VD, et al. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. *J Clin Psychiatry* 2010;71:103–8.
- Bacher NM, Kaup BA. Combining risperidone with standard neuroleptics for refractory schizophrenic patients. *Am J Psychiatry* 1996;153:137.
- Barbui C, Accordini S, Nose M, et al. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial. *J Clin Psychopharmacol* 2011;31:266–73.
- Barnes TR, Paton C. Antipsychotic polypharmacy in schizophrenia: benefits and risks. *CNS Drugs* 2011;25:383–99.
- Barnes TR. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. *J Psychopharmacol* 2011;25:567–620.
- Baynes D, Mulholland C, Cooper SJ, et al. Depressive symptoms in stable chronic schizophrenia: prevalence and relationship to psychopathology and treatment. *Schizophr Res* 2000;45:47–56.
- Behdani F, Hebrani P, Rezaei AA, et al. Effect of topiramate augmentation in chronic schizophrenia: a placebo-controlled trial. *Arch Iran Med* 2011;14:270–5.
- Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. *Am J Psychiatry* 2002;159:1018–28.
- Buchanan RW, Kirkpatrick B, Bryant N, et al. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. *Am J Psychiatry* 1996;153:1625–7.
- Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. *Schizophr Bull* 2010;36:71–93.
- Carlsson A, Waters N, Waters S, et al. Network interactions in schizophrenia – therapeutic implications. *Brain Res Brain Res Rev* 2000;31:342–9.
- Casey DE, Daniel DG, Tamminga C, et al. Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. *Neuropsychopharmacology* 2009;34:1330–8.
- Casey DE, Daniel DG, Wassef AA, et al. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. *Neuropsychopharmacology* 2003;28:182–92.
- Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. *Am J Psychiatry* 2001;158:518–26.
- Chakos MH, Glick ID, Miller AL, et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. *Psychiatr Serv* 2006;57:1094–101.
- Chan J, Sweeting M. Review: Combination therapy with non-clozapine atypical antipsychotic medication: a review of current evidence. *J Psychopharmacol* 2007;21:657–64.
- Chang JS, Ahn YM, Park HJ, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. *J Clin Psychiatry* 2008;69:720–31.
- Chang JS, Lee NY, Ahn YM, et al. The sustained effects of aripiprazole-augmented clozapine treatment on the psychotic symptoms and metabolic profiles of patients with refractory schizophrenia. *J Clin Psychopharmacol* 2012;32:282–4.
- Chue P, Welch R, Snaterse M. Combination risperidone and quetiapine therapy in refractory schizophrenia. *Can J Psychiatry* 2001;46:86–7.
- Cipriani A, Accordini S, Nose M, et al. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial. *J Clin Psychopharmacol* 2013;33:533–7.
- Citrome L, Jaffe A, Levine J, et al. Use of mood stabilizers among patients with schizophrenia, 1994–2001. *Psychiatr Serv* 2002;53:1212.
- Clarke LA, Lindenmayer JP, Kaushik S. Clozapine augmentation with aripiprazole for negative symptoms. *J Clin Psychiatry* 2006;67:675–6.
- Cook B, Hoogenboom G. Combined use of amisulpride and clozapine for patients with treatment-resistant schizophrenia. *Australas Psychiatry* 2004;12:74–6.
- Cooke C, de Leon J. Adding other antipsychotics to clozapine. *J Clin Psychiatry* 1999;60:710.
- Correll CU, Rummel-Kluge C, Corves C, et al. Antipsychotic combinations vs. monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. *Schizophr Bull* 2009;35:443–57.
- Costello LE, Suppes T. A clinically significant interaction between clozapine and valproate. *J Clin Psychopharmacol* 1995;15:139–41.
- Davis KL, Kahn RS, Ko G, et al. Dopamine in schizophrenia: a review and reconceptualization. *Am J Psychiatry* 1991;148:1474–86.

Priv.-Doz. Dr. Thomas Messer, Danuviusklinik GmbH, Krankenhausstraße 68, 8576 Pfaffenhofen,
E-Mail: thomas.messer@danuviusklinik.de
Prof. Dr. Max Schmauß, Bezirkskrankenhaus Augsburg, Dr.-Mack-Straße 1, 86156 Augsburg

36. De HM, van WR, Wampers M, et al. Remission criteria for schizophrenia: evaluation in a large naturalistic cohort. *Schizophr Res* 2007;92:68–73.
37. De RA, Pancheri A, Simonetti G, et al. Add-on of aripiprazole improves outcome in clozapine-resistant schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 2011;35:1112–6.
38. Delva NJ, Letemendia FJ. Lithium treatment in schizophrenia and schizo-affective disorders. *Br J Psychiatry* 1982;141:387–400.
39. Dolder CR, Lacro JP, Dunn LB, et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? *Am J Psychiatry* 2002;159:103–8.
40. Donaldson SR, Gelenberg AJ, Baldessarini RJ. The pharmacologic treatment of schizophrenia: a progress report. *Schizophr Bull* 1983;9:504–27.
41. Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss. *Can J Psychiatry* 2000;45:198.
42. Essock SM, Schooler NR, Stroup TS, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. *Am J Psychiatry* 2011;168:702–8.
43. Farber NB, Kim SH, Dikranian K, et al. Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. *Mol Psychiatry* 2002;7:32–43.
44. Faries D, Scher-Svanum H, Zhu B, et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. *BMC Psychiatry* 2005;5:26.
45. Fleischhacker WW, Heikkinen ME, Olie JP, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. *Int J Neuropsychopharmacol* 2010;13:1115–25.
46. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. *Acta Psychiatr Scand* 2002;106:323–30.
47. Freudenreich O, Henderson DC, Walsh JP, et al. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. *Schizophr Res* 2007;92:90–4.
48. Gallego JA, Bonetti J, Zhang J, et al. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. *Schizophr Res* 2012;138:18–28.
49. Ganguly R, Kotzan JA, Miller LS, et al. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998–2000. *J Clin Psychiatry* 2004;65:1377–88.
50. Genc Y, Taner E, Candansayar S. Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. *Adv Ther* 2007;24:1–13.
51. George S, Cowan C. Effectiveness of amisulpride augmentation of clozapine in a non-responder to either drug alone: a case report. *Acta Psychiatr Scand* 2005;111:163.
52. Gerson SL, Lieberman JA, Friedenber WR, et al. Polypharmacy in fatal clozapine-associated agranulocytosis. *Lancet* 1991;338:262–3.
53. Ghaemi SN. Polypharmacy in Psychiatry. Oepen G. Polypharmacy in Schizophrenia. In: Ghaemi SN. Polypharmacy in Psychiatry. New York: Marcel Dekker Inc., 2002:101–32.
54. Ghaleiha A, Noorbala AA, Farnaghi F, et al. A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia. *J Clin Psychopharmacol* 2010;30:678–82.
55. Gilmer TP, Dolder CR, Folsom DP, et al. Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999–2004. *Psychiatr Serv* 2007;58:1007–10.
56. Godleski LS, Kerler R, Barber JW, et al. Multiple versus single antipsychotic drug treatment in chronic psychosis. *J Nerv Ment Dis* 1989;177:686–9.
57. Goff DC, Keefe R, Citrome L, et al. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. *J Clin Psychopharmacol* 2007;27:582–9.
58. Goff DC, Midha KK, Sarid-Segal O, et al. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. *Psychopharmacology (Berl)* 1995;117:417–23.
59. Green MF, Kern RS, Braff DL, et al. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the „right stuff“? *Schizophr Bull* 2000;26:119–36.
60. Grohmann R, Ruther E, Sassim N, et al. Adverse effects of clozapine. *Psychopharmacology (Berl)* 1989;99(Suppl):S101–4.
61. Grove GA, Crayton JW, Klass DB, et al. Lithium in chronic schizophrenia. *Am J Psychiatry* 1979;136:454–5.
62. Gupta S, Sonnenberg SJ, Frank B. Olanzapine augmentation of clozapine. *Ann Clin Psychiatry* 1998;10:113–5.
63. Häfner H. Schizophrenie – von der Tradition zur Gegenwart. *Neurotransmitter* 2004;4:64–8.
64. Hahn MK, Remington G, Bois D, Cohn T. Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects. *J Clin Psychopharmacol* 2010;30:706–10.
65. Haller E, Binder RL. Clozapine and seizures. *Am J Psychiatry* 1990;147:1069–71.
66. Harrow M, Yonan CA, Sands JR, et al. Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved? *Schizophr Bull* 1994;20:327–38.
67. Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. *World J Biol Psychiatry* 2012;13:318–78.
68. Henderson DC, Fan X, Copeland PM, et al. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. *J Clin Psychopharmacol* 2009;29:165–9.
69. Hertling I, Philipp M, Dvorak A, et al. Flupenthixol versus risperidone: subjective quality of life as an important factor for compliance in chronic schizophrenic patients. *Neuropsychobiology* 2003;47:37–46.
70. Honer WG, Thornton AE, Chen EY, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. *N Engl J Med* 2006;354:472–82.
71. Huttunen MO, Tuhkanen H, Haavisto E, et al. Low- and standard-dose depot haloperidol combined with targeted oral neuroleptics. *Psychiatr Serv* 1996;47:83–5.
72. Johnson DA. The significance of depression in the prediction of relapse in chronic schizophrenia. *Br J Psychiatry* 1988;152:320–3.
73. Josiassen RC, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. *Am J Psychiatry* 2005;162:130–6.
74. Junghan U, Albers M, Woggon B. Increased risk of hematological side-effects in psychiatric patients treated with clozapine and carbamazepine? *Pharmacopsychiatry* 1993;26:262.
75. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. *Lancet* 2008;371:1085–97.
76. Kampf P, Agelink MW, Naber D. Augmentation of clozapine with amisulpride: a promising therapeutic approach to refractory schizophrenic symptoms. *Pharmacopsychiatry* 2005;38:39–40.
77. Kando JC, Tohen M, Castillo J, et al. Concurrent use of clozapine and valproate in affective and psychotic disorders. *J Clin Psychiatry* 1994;55:255–7.
78. Kane JM, Correll CU, Goff DC, et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. *J Clin Psychiatry* 2009;70:1348–57.
79. Kapur S, Roy P, Daskalakis J, et al. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. *Am J Psychiatry* 2001;158:311–4.
80. Karow A, Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. *Psychopharmacology (Berl)* 2002;162:3–10.
81. Karunakaran K, Tungaraza TE, Harborne GC. Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia? *J Psychopharmacol* 2007;21:453–6.
82. Kasckow JW, Mohamed S, Thallasinos A, et al. Citalopram augmentation of antipsychotic treatment in older schizophrenia patients. *Int J Geriatr Psychiatry* 2001;16:1163–7.
83. Kaye NS. Ziprasidone augmentation of clozapine in 11 patients. *J Clin Psychiatry* 2003;64:215–6.

84. Kennedy NB, Procyshyn RM. Rational antipsychotic polypharmacy. *Can J Clin Pharmacol* 2000;7:155–9.
85. Kilian R, Dietrich S, Toumi M, et al. Quality of life in persons with schizophrenia in outpatient treatment with first- or second-generation antipsychotics. *Acta Psychiatr Scand* 2004;110:108–18.
86. Kim JH, Yim SJ, Nam JH. A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. *Schizophr Res* 2006;82:115–7.
87. Kirli S, Caliskan M. A comparative study of sertraline versus imipramine in postpsychotic depressive disorder of schizophrenia. *Schizophr Res* 1998;33:103–11.
88. Kishimoto T, Agarwal V, Kishi T, et al. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. *Mol Psychiatry* 2013;18:53–66.
89. Ko YH, Joe SH, Jung IK, et al. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. *Clin Neuropharmacol* 2005;28:169–75.
90. Kotler M, Strous RD, Reznik I, et al. Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology. *Int Clin Psychopharmacol* 2004;19:23–6.
91. Kreinin A, Miodownik C, Sokolik S, et al. Amisulpride versus moclobemide in treatment of clozapine-induced hypersalivation. *World J Biol Psychiatry* 2011;12:620–6.
92. Kremer I, Vass A, Gorelik I, et al. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. *Biol Psychiatry* 2004;56:441–6.
93. Krivoy A, Malka L, Fischel T, et al. Predictors of clozapine discontinuation in patients with schizophrenia. *Int Clin Psychopharmacol* 2011;26:311–5.
94. Lee MS, Han CS, You YW, et al. Co-administration of sertraline and haloperidol. *Psychiatry Clin Neurosci* 1998;52(Suppl):S193–8.
95. Lee MS, Kim YK, Lee SK, et al. A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia. *J Clin Psychopharmacol* 1998;18:399–403.
96. Lerner V, Bergman J, Borokhov A, et al. Augmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy. *Clin Neuropharmacol* 2005;28:66–71.
97. Lerner V, Chudakova B, Kravets S, et al. Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report. *Clin Neuropharmacol* 2000;23:284–6.
98. Lerner V, Libov I, Kotler M, et al. Combination of „atypical“ antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 2004;28:89–98.
99. Leucht S, Heres S, Kissling W, et al. Evidence-based pharmacotherapy of schizophrenia. *Int J Neuropsychopharmacol* 2011;14:269–84.
100. Leucht S, Kissling W, McGrath J, et al. Carbamazepine for schizophrenia. *Cochrane Database Syst Rev* 2007;3:CD001258.
101. Leucht S, Kissling W, McGrath J. Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials. *J Clin. Psychiatry* 2004;65:177–86.
102. Leucht S, Kissling W, McGrath J. Lithium for schizophrenia. *Cochrane Database Syst Rev* 2007;(3):CD003834.
103. Leucht S, McGrath J, Kissling W. Lithium for schizophrenia. *Cochrane Database Syst Rev* 2003;(3):CD003834.
104. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. *Lancet* 2012;379:2063–71.
105. Levinson DF, Umapathy C, Musthaq M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms. *Am J Psychiatry* 1999;156:1138–48.
106. Levy E, Margolese HC, Chouinard G. Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia. *J Clin Psychiatry* 2002;63:1045.
107. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med* 2005;353:1209–23.
108. Lim S, Bowers MB. Augmentation of clozapine treatment with aripiprazole. *J Clin Psychiatry* 2007;68:798–9.
109. Linden M, Scheel T, Xaver EF. Dosage finding and outcome in the treatment of schizophrenic inpatients with amisulpride. Results of a drug utilization observation study. *Hum Psychopharmacol* 2004;19:111–9.
110. Luchins DJ. Fatal agranulocytosis in a chronic schizophrenic patient treated with carbamazepine. *Am J Psychiatry* 1984;141:687–8.
111. Luchins DJ. Fatal agranulocytosis in a chronic schizophrenic patient treated with carbamazepine. *Am J Psychiatry* 1984;141:687–8.
112. Masopust J, Tuma I, Libiger J. Adjunctive aripiprazole decreased metabolic side effects of clozapine treatment. *Neuro Endocrinol Lett* 2008;29:435–7.
113. Meltzer H, Kostakoglu A. Combining antipsychotics: Is there evidence for efficacy? *Psychiatric Times* 2004;XVII(9).
114. Mitsonis CI, Dimopoulos NP, Mitropoulos PA, et al. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study. *Prog Neuropsychopharmacol Biol Psychiatry* 2007;31:373–7.
115. Möller HJ, Seemüller F, Schennach-Wolff R, et al. History, background, concepts and current use of comedication and polypharmacy in psychiatry. *Int J Neuropsychopharmacol* 2014;17:983–96.
116. Müller MJ, Wetzel H. Dimensionality of depression in acute schizophrenia: a methodological study using the Bech-Rafaelsen Melancholia Scale (BRMES). *J Psychiatr Res* 1998;32:369–78.
117. Müller T, Becker T, Fritze J. Neuroleptic malignant syndrome after clozapine plus carbamazepine. *Lancet* 1988;2:1500.
118. Munro J, Matthiasson P, Osborne S, et al. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. *Acta Psychiatr Scand* 2004;110:292–8.
119. Muscatello MR, Bruno A, Pandolfo G, et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. *Schizophr Res* 2011;127:93–9.
120. Muscatello MR, Bruno A, Pandolfo G, et al. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. *J Psychopharmacol* 2011;25:667–74.
121. Navarro V, Pons A, Romero A, et al. Topiramate for clozapine-induced seizures. *Am J Psychiatry* 2001;158:968–9.
122. Paton C, Barnes TR, Cavanagh MR, et al. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. *Br J Psychiatry* 2008;192:435–9.
123. Paton C, Whittington C, Barnes TR. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. *J Clin Psychopharmacol* 2007;27:198–204.
124. Peacock L, Gerlach J. Clozapine treatment in Denmark: concomitant psychotropic medication and hematologic monitoring in a system with liberal usage practices. *J Clin Psychiatry* 1994;55:44–9.
125. Peuskens J, Van Baelen B, De Smedt C, et al. Effects of risperidone on affective symptoms in patients with schizophrenia. *Int Clin Psychopharmacol* 2000;15:343–9.
126. Pigato G, Toffanin T, Perini GI. Is a high dosage aripiprazole-clozapine combination an effective strategy for treatment-resistant schizophrenic patients? A case report. *Prog Neuropsychopharmacol Biol Psychiatry* 2009;33:153–5.
127. Potkin SG, Thyrum PT, Alva G, et al. The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. *J Clin Psychopharmacol* 2002;22:121–30.
128. Procyshyn RM, Honer WG, Wu TK, et al. Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. *J Clin Psychiatry* 2010;71:566–73.
129. Raskin S, Durst R, Katz G, et al. Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia. *J Clin Psychopharmacol* 2000;20:500–3.
130. Rhoads E. Polypharmacy of 2 atypical antipsychotics. *J Clin Psychiatry* 2000;61:678–80.
131. Ritsner M, Gibel A, Perelroyzen G, et al. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. *J Clin Psychopharmacol* 2004;24:582–91.

132. Rittmannsberger H, Leblhuber F, Sommer R. Asterixis as a side effect of carbamazepine therapy. *Klin Wochenschr* 1991;69:279–81.
133. Rittmannsberger H, Leblhuber F. Asterixis induced by carbamazepine therapy. *Biol Psychiatry* 1992;32:364–8.
134. Rocha FL, Hara C. Benefits of combining aripiprazole to clozapine: three case reports. *Prog Neuropsychopharmacol Biol Psychiatry* 2006;30:1167–9.
135. Rothbard AB, Kuno E, Foley K. Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. *Schizophr Bull* 2003;29:531–40.
136. Rummel C, Kissling W, Leucht S. Antidepressants for the negative symptoms of schizophrenia. *Cochrane Database Syst Rev* 2006;3:CD005581.
137. Rupnow MF, Greenspan A, Gharabawi GM, et al. Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. *Curr Med Res Opin* 2007;23:2815–22.
138. Salokangas RK, Saarijarvi S, Taiminen T, et al. Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. *Acta Psychiatr Scand* 1996;94:175–80.
139. Sands JR, Harrow M. Depression during the longitudinal course of schizophrenia. *Schizophr Bull* 1999;25:157–71.
140. Schulz SC, Thompson PA, Jacobs M, et al. Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients. *J Clin Psychiatry* 1999;60:366–72.
141. Schwarz C, Volz A, Li C, et al. Valproate for schizophrenia. *Cochrane Database Syst Rev* 2008;(3):CD004208.
142. Sepehry AA, Potvin S, Elie R, et al. Selective serotonin reuptake inhibitor (SSRI) addition therapy for the negative symptoms of schizophrenia: a meta-analysis. *J Clin Psychiatry* 2007;68:604–10.
143. Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. *Br J Psychiatry* 1997;171:569–73.
144. Sim K, Su A, Fujii S, et al. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. *Br J Clin Pharmacol* 2004;58:178–83.
145. Simhandl C, Meszaros K. The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: a review. *J Psychiatry Neurosci* 1992;17:1–14.
146. Singh SP, Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. *CNS Drugs* 2011;25:859–85.
147. Siris SG, Bermanzohn PC, Mason SE, et al. Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial. *Arch Gen Psychiatry* 1994;51:109–15.
148. Siris SG. Depression in schizophrenia: perspective in the era of „atypical“ antipsychotic agents. *Am J Psychiatry* 2000;157:1379–89.
149. Small JG, Kellams JJ, Milstein V, et al. A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. *Am J Psychiatry* 1975;132:1315–7.
150. Small JG, Klapper MH, Malloy FW, et al. Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder. *J Clin Psychopharmacol* 2003;23:223–8.
151. Stahl SM. Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret? *J Clin Psychiatry* 1999;60:425–6.
152. Strasser O, Schmauss M, Messer T. [Rehospitalization rates of newly diagnosed schizophrenic patients on atypical neuroleptic medication]. *Psychiatr Prax* 2004;31(Suppl 1):S38–40.
153. Suzuki T, Remington G, Mulsant BH, et al. Treatment resistant schizophrenia and response to antipsychotics: a review. *Schizophr Res* 2011;133:54–62.
154. Suzuki T, Uchida H, Watanabe K, et al. Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. *Hum Psychopharmacol* 2008;23:455–63.
155. Takahashi H, Sugita T, Higuchi H, et al. Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial. *Hum Psychopharmacol* 2002;17:95–8.
156. Takhar J. Pimozide augmentation in a patient with drug-resistant psychosis previously treated with olanzapine. *J Psychiatry Neurosci* 1999;24:248–9.
157. Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. *Psychoneuroendocrinology* 2003;28(Suppl):19–26.
158. Tapp A, Wood AE, Secrest L, et al. Combination antipsychotic therapy in clinical practice. *Psychiatr Serv* 2003;54:55–9.
159. Tiihonen J, Hallikainen T, Ryyanen OP, et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. *Biol Psychiatry* 2003;54:1241–8.
160. Tiihonen J, Suokas JT, Suvisaari JM, et al. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. *Arch Gen Psychiatry* 2012;69:476–83.
161. Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. *Schizophr Res* 2009;109:10–4.
162. Tollefson GD, Sanger TM, Lu Y, et al. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. *Arch Gen Psychiatry* 1998;55:250–8.
163. Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. *Schizophr Res* 2005;72:225–34.
164. Tuunainen A, Wahlbeck K, Gilbody S. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. *Schizophr Res* 2002;56:1–10.
165. Volz A, Khorsand V, Gillies D, et al. Benzodiazepines for schizophrenia. *Cochrane Database Syst Rev* 2007;(1):CD006391.
166. Voruganti L, Cortese L, Ouyewumi L, et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. *Schizophr Res* 2002;57:201–8.
167. Voruganti L, Cortese L, Ouyewumi L, et al. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. *Schizophr Res* 2000;43:135–45.
168. Wassink TH, Flaum M, Nopoulos P, et al. Prevalence of depressive symptoms early in the course of schizophrenia. *Am J Psychiatry* 1999;156:315–6.
169. Wirshing WC, Ames D, Bisheff S, et al. Hepatic encephalopathy associated with combined clozapine and divalproex sodium treatment. *J Clin Psychopharmacol* 1997;17:120–1.
170. Xiang YT, Weng YZ, Leung CM, et al. Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia. *Pharmacopsychiatry* 2007;40:47–52.
171. Ziegenbein M, Kropp S, Kuenzel HE. Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: an open clinical study. *Clin Neuropharmacol* 2005;28:220–4.
172. Ziegenbein M, Wittmann G, Kropp S. Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia: a clinical observation. *Clin Drug Investig* 2006;26:117–24.
173. Zink M, Knopf U, Henn FA, et al. Combination of clozapine and amisulpride in treatment-resistant schizophrenia – case reports and review of the literature. *Pharmacopsychiatry* 2004;37:26–31.
174. Zink M, Kuwilsky A, Krumm B, et al. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. *J Psychopharmacol* 2009;23:305–14.
175. Zink M, Mase E, Dressing H. [Ziprasidone-augmentation of clozapine]. *Psychiatr Prax* 2004;31:259–61.
176. Zink M, Mase E, Dressing H. Combination of ziprasidone and clozapine in treatment-resistant schizophrenia. *Hum Psychopharmacol* 2004;19:271–3.
177. Zisook S, McAdams LA, Kuck J, et al. Depressive symptoms in schizophrenia. *Am J Psychiatry* 1999;156:1736–43.
178. Zoccali R, Muscatello MR, Bruno A, et al. The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. *Schizophr Res* 2007;93:109–16.